Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we report that 1) anandamide and 2-AG inhibit the nerve growth factor (NGF)-induced proliferation of HBCCs through suppression of the levels of NGF Trk receptors; 2) inhibition of PRLr levels results in inhibition of the proliferation of other PRL-responsive cells, the prostate cancer DU-145 cell line; and 3) CB1-like cannabinoid receptors are expressed in HBCCs and DU-145 cells and mediate the inhibition of cell proliferation and Trk/PRLr expression. Beta-NGF-induced HBCC proliferation was potently inhibited (IC50 = 50-600 nM) by the synthetic cannabinoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but not by the anandamide congener, palmitoylethanolamide, or the selective agonist of CB2 cannabinoid receptors, BML-190. The effect of anandamide was blocked by the CB1 receptor antagonist, SR141716A, but not by the CB2 receptor antagonist, SR144528. Anandamide and HU-210 exerted a strong inhibition of the levels of NGF Trk receptors as detected by Western immunoblotting; this effect was reversed by SR141716A. When induced by exogenous PRL, the proliferation of prostate DU-145 cells was potently inhibited (IC50 = 100-300 nM) by anandamide, 2-AG, and HU-210. Anandamide also down-regulated the levels of PRLr in DU-145 cells. SR141716A attenuated these two effects of anandamide. HBCCs and DU-145 cells were shown to contain 1) transcripts for CB1 and, to a lesser extent, CB2 cannabinoid receptors, 2) specific binding sites for [3H]SR141716A that could be displaced by anandamide, and 3) a CB1 receptor-immunoreactive protein. These findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential negative effectors of PRL- and NGF-induced biological responses, at least in some cancer cells.

[1]  T. Bisogno,et al.  Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. , 1999, Biochemical and biophysical research communications.

[2]  L. Petrocellis,et al.  Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. , 1999, European journal of biochemistry.

[3]  J. Manzanares,et al.  Identification of Endocannabinoids and Cannabinoid CB1 Receptor mRNA in the Pituitary Gland , 1999, Neuroendocrinology.

[4]  R. Duman,et al.  Stimulation of Adenylyl Cyclase and Induction of Brain‐Derived Neurotrophic Factor and TrkB mRNA by NKH477, a Novel and Potent Forskolin Derivative , 1999, Journal of neurochemistry.

[5]  N. Kaminski,et al.  Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. , 1998, Toxicology letters.

[6]  L. Petrocellis,et al.  Trick or treat from food endocannabinoids? , 1998, Nature.

[7]  A. Lichtman,et al.  Cannabinoid Transmission and Pain Perception , 1998, Neurobiology of Disease.

[8]  L. Petrocellis,et al.  Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action , 1998, Trends in Neurosciences.

[9]  L. Murphy,et al.  Function of Cannabinoid Receptors in the Neuroendocrine Regulation of Hormone Secretion , 1998, Neurobiology of Disease.

[10]  G. Kunos,et al.  Cardiovascular actions of cannabinoids and their generation during shock , 1998, Journal of Molecular Medicine.

[11]  D. Djakiew,et al.  Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor–induced cell growth by activation of programmed cell death , 1998, Molecular carcinogenesis.

[12]  E. Hooghe-Peters,et al.  Prolactin, growth hormone and the immune system in humans , 1998, Cellular and Molecular Life Sciences CMLS.

[13]  S. Yamamoto,et al.  A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. , 1998, The journal of medical investigation : JMI.

[14]  L. Petrocellis,et al.  The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Hondermarck,et al.  Nerve Growth Factor Is Mitogenic for Cancerous but Not Normal Human Breast Epithelial Cells* , 1998, The Journal of Biological Chemistry.

[16]  L. Petrocellis,et al.  Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. , 1998, European journal of biochemistry.

[17]  L. Lauritzen,et al.  Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity. , 1998 .

[18]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[19]  P. Kelly,et al.  Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[20]  T. Bonner,et al.  Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies , 1998, Journal of Neuroimmunology.

[21]  J. D. Richardson,et al.  Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia , 1998, The Journal of Neuroscience.

[22]  L. Hennighausen,et al.  Prolactin Signaling in Mammary Gland Development* , 1997, The Journal of Biological Chemistry.

[23]  T. Bisogno,et al.  Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes* , 1997, The Journal of Biological Chemistry.

[24]  P. Prasit,et al.  New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor. , 1997 .

[25]  J. Taylor,et al.  Failure of cannabinoid compounds to stimulate estrogen receptors. , 1997, Biochemical pharmacology.

[26]  S. Skaper,et al.  Nerve growth factor: from neurotrophin to neurokine , 1996, Trends in Neurosciences.

[27]  P. Prasit,et al.  NEW CLASS OF POTENT LIGANDS FOR THE HUMAN PERIPHERAL CANNABINOID RECEPTOR , 1996 .

[28]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[29]  G. Fuh,et al.  Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines (*) , 1995, The Journal of Biological Chemistry.

[30]  J. Tomaszewski,et al.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. , 1995, The American journal of pathology.

[31]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[32]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[33]  A. Stalder,et al.  Expression of functional trk protooncogene in human monocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[35]  J. Wrathall,et al.  Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. , 1991, Cancer research.

[36]  A. Zentella,et al.  Pancreatic b cells synthesize and secrete nerve growth factor , 1998 .

[37]  V. Di Marzo.  'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. , 1998, Biochimica et biophysica acta.

[38]  R. Levi‐montalcini.  The saga of the nerve growth factor. , 1998, Neuroreport.

[39]  D. Newling,et al.  Neurotrophic factors in prostate and prostatic cancer , 1998, Prostate Cancer and Prostatic Diseases.

[40]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[41]  R. Kiss,et al.  In vitro characterization of prolactin‐induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate , 1996, Cancer.

[42]  F. Chilton,et al.  Arachidonate-phospholipid remodeling and cell proliferation. , 1996, Advances in experimental medicine and biology.

[43]  T. Sugiura,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.